Follow the people · Insider
Jennifer Tousignant
Jennifer Tousignant files insider transactions with the SEC as a chief legal officer of Viridian Therapeutics, Inc.\DE (VRDN). We hold 2 disclosed purchases and sales filed since 14 February 2024, 1 of them in the last 90 days.
- Files forVRDN
- Disclosed buys and sells2 in all, 1 in the last 90 days
- Last disclosure20 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 12 February 2024 — 19 August 2026Chief Legal Officer · Viridian Therapeutics, Inc.\DE (VRDN)21 Form 4 lines · source: SEC Form 4
Everything they disclosed
21 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 4,212 shares of Viridian Therapeutics, Inc.\DESEC Form 420 August 2026Common Stock · traded 19 August 2026 · filed 20 August 2026
- exercised options over 10,000 shares of Viridian Therapeutics, Inc.\DESEC Form 420 August 2026Common Stock · traded 19 August 2026 · filed 20 August 2026
- ▼ sold on the open market 10,000 shares of Viridian Therapeutics, Inc.\DESEC Form 420 August 2026Common Stock · traded 19 August 2026 · filed 20 August 2026
- exercised options over 10,000 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 420 August 2026Stock Option (Right to Buy) · traded 19 August 2026 · filed 20 August 2026
- had shares withheld for tax on 1,675 shares of Viridian Therapeutics, Inc.\DESEC Form 49 March 2026Common Stock · traded 3 March 2026 · filed 9 March 2026
- had shares withheld for tax on 1,675 shares of Viridian Therapeutics, Inc.\DESEC Form 49 March 2026Common Stock · traded 3 March 2026 · filed 9 March 2026
- exercised options over 5,169 shares of Viridian Therapeutics, Inc.\DESEC Form 44 March 2026Common Stock · traded 3 March 2026 · filed 4 March 2026
- had shares withheld for tax on 1,724 shares of Viridian Therapeutics, Inc.\DESEC Form 44 March 2026Common Stock · traded 3 March 2026 · filed 4 March 2026
- was granted 119,300 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 44 March 2026Stock Option (Right to Buy) · traded 2 March 2026 · filed 4 March 2026
- was granted 119,300 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 44 March 2026Stock Option (Right to Buy) · traded 2 March 2026 · filed 4 March 2026
- was granted 23,850 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 44 March 2026Restricted Stock Units · traded 2 March 2026 · filed 4 March 2026
- exercised options over 5,169 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 44 March 2026Restricted Stock Units · traded 3 March 2026 · filed 4 March 2026
- was granted 23,850 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 44 March 2026Restricted Stock Units · traded 2 March 2026 · filed 4 March 2026
- exercised options over 5,169 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 44 March 2026Restricted Stock Units · traded 3 March 2026 · filed 4 March 2026
- exercised options over 5,169 shares of Viridian Therapeutics, Inc.\DESEC Form 44 March 2026Common Stock · traded 3 March 2026 · filed 4 March 2026
- had shares withheld for tax on 1,724 shares of Viridian Therapeutics, Inc.\DESEC Form 44 March 2026Common Stock · traded 3 March 2026 · filed 4 March 2026
- ▼ sold on the open market 2,272 shares of Viridian Therapeutics, Inc.\DESEC Form 42 January 2026Common Stock · traded 31 December 2025 · filed 2 January 2026
- ▼ sold on the open market 2,272 shares of Viridian Therapeutics, Inc.\DESEC Form 42 January 2026Common Stock · traded 31 December 2025 · filed 2 January 2026
- was granted 124,072 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 44 March 2025Stock Option (Right to Buy) · traded 3 March 2025 · filed 4 March 2025
- was granted 20,679 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 44 March 2025Restricted Stock Units · traded 3 March 2025 · filed 4 March 2025
- was granted 290,000 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 414 February 2024Stock Option (Right to Buy) · traded 12 February 2024 · filed 14 February 2024
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.